---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-164010"
form_type: "8-K"
ticker: "IRON"
cik: "0001816736"
company_name: "Disc Medicine, Inc."
filed_at: "2023-06-09T23:59:59+00:00"
generated_at: "2026-06-14T04:10:11.837226+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Disc Medicine reports positive Phase 2 bitopertin data in EPP: PPIX down >40%, sunlight tolerance up >80-fold

## Summary
- Mean reduction of whole-blood PPIX >40% in dose-dependent, sustained manner across 15 patients.
- Two patients with longest follow-up: >80-fold (20 mg) and >200-fold (60 mg) increase in sunlight tolerance without prodrome.
- Average weekly sunlight exposure rose from 344 min at baseline to 1,200 min at Week 24; time to prodrome increased >7-fold.
- Patient-reported phototoxic reactions reduced 96% vs. baseline; all 10 patients at Day 43 reported disease much/a little better on PGIC.
- Bitopertin well-tolerated: no serious AEs, no discontinuations, no grade >1 AEs, no meaningful hemoglobin changes.

## SEC filing metadata
- accession: 0001193125-23-164010
- form_type: 8-K
- ticker: IRON
- cik: 0001816736
- company_name: Disc Medicine, Inc.
- filed_at: 2023-06-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816736/000119312523164010/0001193125-23-164010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816736/000119312523164010/d350054d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-164010
- JSON: https://secwatch.observer/filing/0001193125-23-164010.json
- Plain text: https://secwatch.observer/filing/0001193125-23-164010.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.